Abstract The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a
World Health Organization workshop in 1999. The initial goals were (1) to propose a new …

The selection of pharmacotherapy for patients with allergic rhinitis (AR) depends on several
factors, including age, prominent symptoms, symptom severity, control of AR, patient …

Background Allergic rhinitis (AR) affects 10% to 40% of the population. It reduces quality of
life and school and work performance and is a frequent reason for office visits in general …

Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline by using the
best approach to integrated care pathways using mobile technology in patients with allergic …

Abstract Aims Mobile Airways Sentinel NetworK (MASK) belongs to the Fondation
Partenariale MACVIA‐LR of Montpellier, France and aims to provide an active and healthy …

Allergies are usually referred to as type I hypersensitivity reactions against innocuous
environmental antigens, characterized by a Th2/IgE‐dominated inflammation. They can …

Background In all societies, the burden and cost of allergic and chronic respiratory diseases
are increasing rapidly. Most economies are struggling to deliver modern health care …

MASK‐air®, a validated mHealth app (Medical Device regulation Class IIa) has enabled
large observational implementation studies in over 58,000 people with allergic rhinitis …

Drug repurposing is a major field of value-added medicine. It involves investigating and
evaluating existing drugs for new therapeutic purposes that address unmet healthcare …

Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing (EIP
on AHA) focuses on the integrated care of chronic diseases. Area 5 (Care Pathways) was …